(lp0
S'Sunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare ... Yahoo Finance - 19 hours ago SOUTH SAN FRANCISCO, Calif., March 28, 2017  -- Sunesis Pharmaceuticals, Inc.  today announced that Eric Bjerkholt, Executive Vice President Corporate Development and Finance and Chief Financial Officer of Sunesis, will&nbsp;...Spot Check on Stock With Abnormal Activity Sunesis Pharmaceuticals, Inc ... - Melville Review'
p1
aS'Sunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 ... GlobeNewswire  - Mar 22, 2017 SOUTH SAN FRANCISCO, Calif., March 22, 2017  -- Sunesis Pharmaceuticals, Inc.  today announced that it has submitted its responses to the European Medicine Agency  Day 180 List of Outstanding Issues issued&nbsp;...'
p2
aS'Street Predictions for Sunesis Pharmaceuticals, Inc.  Aiken Advocate - 18 hours ago Using data provided from various analysts, shares of Sunesis Pharmaceuticals, Inc.  are presently listed with an ABR of 2.33.'
p3
aS"SUNESIS PHARMACEUTICALS, INC.  Files An 8-K Results of Operations ... Market Exclusive - Mar 9, 2017 Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers.Sunesis Pharmaceuticals'  CEO Daniel Swisher on Q4 2016 Results ... - Seeking Alpha"
p4
aS"Sunesis Pharmaceuticals Announces Poster Presentation on Preliminary Results ... GlobeNewswire  - Sep 1, 2016 SOUTH SAN FRANCISCO, Calif., Sept. 01, 2016  -- Sunesis Pharmaceuticals, Inc.  today announced that a poster detailing preliminary results from the Company's Phase 1A study in healthy volunteers evaluating oral&nbsp;..."
p5
aS'Sunesis Pharmaceuticals Announces 1-for-6 Reverse Stock Split GlobeNewswire  - Sep 7, 2016 SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016  -- Sunesis Pharmaceuticals, Inc.  today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-6&nbsp;...'
p6
aS'Sunesis Pharmaceuticals updates on SNS-062 and Vosaroxin programs Seeking Alpha - Jan 23, 2017 Sunesis Pharmaceuticals  announces clinical and regulatory updates to its two lead programs, SNS-062, a second-generation reversible and non-covalent BTK inhibitor, and vosaroxin, an anti-cancer quinolone derivative currently under review ...'
p7
aS'Sunesis Pharmaceuticals Inc.: Sunesis to Host Conference Call on March 9th to ... The Wall Street Transcript - Mar 2, 2017 SOUTH SAN FRANCISCO, Calif., March 02, 2017  -- Sunesis Pharmaceuticals, Inc.  today announced that it will host a conference call on Thursday, March 9, 2017 at 11:00 a.m.Sunesis Pharmaceuticals, Inc.  Valuation According To Analysts - UK Market News'
p8
aS'Cowen Comments on Sunesis Pharmaceuticals, Inc.  Following 2Q:16 Update Smarter Analyst - Jul 29, 2016 Cowen analyst Eric Schmidt weighed in today with a few insights on Sunesis Pharmaceuticals, Inc. , after the company reported second-quarter financials and provided investors with an update on its regulatory and clinical progress.'
p9
aS"Sunesis Pharmaceuticals Announces Presentation of Positive Results from MD ... GlobeNewswire  - Jun 13, 2016 Sunesis also announced that follow-up data from the company's VALOR trial was presented as an e-poster during the EHA meeting."
p10
a.